DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Dok Hyun | ko |
dc.contributor.author | Koh, Youngil | ko |
dc.contributor.author | Jung, Miyoung | ko |
dc.contributor.author | Kwak, Jeong-Eun | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.contributor.author | Hwang, Yu Kyeong | ko |
dc.contributor.author | Kim, Won Seog | ko |
dc.date.accessioned | 2023-12-06T02:01:24Z | - |
dc.date.available | 2023-12-06T02:01:24Z | - |
dc.date.created | 2023-12-06 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.citation | TRANSPLANTATION AND CELLULAR THERAPY, v.29, no.4, pp.253e1 - 253e9 | - |
dc.identifier.issn | 2666-6375 | - |
dc.identifier.uri | http://hdl.handle.net/10203/315794 | - |
dc.description.abstract | The prognosis of non-Hodgkin lymphoma (NHL) remains poor, with an unmet need for novel therapies. MG4101, an ex vivo-expanded allogeneic natural killer (NK) cell, can enhance rituximab antibody-dependent cytotoxicity in relapsed/refractory (r/r) B cell non-Hodgkin lymphoma. This study assessed the safety and efficacy of MG4101 plus rituximab for patients with r/r NHL. Patients received escalating doses of i.v. MG4101 plus rituximab every 2 weeks. IL-2 was administered s.c. after MG4101 treatment. Fludarabine plus cyclophosphamide was administered i.v. before rituximab treatment in cycles 1, 3, and 5. A 3+3 design was used to determine the maximum tolerated dose (MTD) and maximum feasible dose. Assessments were performed over a 6-cycle period, with an extended maintenance period of up to 8 cycles. Nine patients received 3 different doses of MG4101 and rituximab. MTD could not be determined because of the absence of dose-limiting toxicity. Treatment-related adverse events, mostly grade 1 or 2, occurred in 89% of patients. Only 1 patient experienced grade 1 cytokine release syndrome. MG4101 persisted for at least 7 days in 7 patients. Four patients achieved a partial response and 1 patient attained a complete response, for an overall response rate of 55.6%. Two patients showed prolonged responses and low exhaustion marker levels in T cells. For allogeneic NK cell therapy, strategies including the use of the high-affinity hFc gamma RIIIaV158 variant of the KIR B/x haplotype with lymphodepleting chemotherapy may be promising options for improving clinical efficacy in the antibody combination therapeutic setting as an off-the-shelf product. MG4101 plus rituximab presented a favorable safety profile and overall response rate in patients with r/r NHL (c) 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma | - |
dc.type | Article | - |
dc.identifier.wosid | 000974902000001 | - |
dc.identifier.scopusid | 2-s2.0-85150457654 | - |
dc.type.rims | ART | - |
dc.citation.volume | 29 | - |
dc.citation.issue | 4 | - |
dc.citation.beginningpage | 253e1 | - |
dc.citation.endingpage | 253e9 | - |
dc.citation.publicationname | TRANSPLANTATION AND CELLULAR THERAPY | - |
dc.identifier.doi | 10.1016/j.jtct.2022.12.025 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Yoon, Dok Hyun | - |
dc.contributor.nonIdAuthor | Koh, Youngil | - |
dc.contributor.nonIdAuthor | Jung, Miyoung | - |
dc.contributor.nonIdAuthor | Kwak, Jeong-Eun | - |
dc.contributor.nonIdAuthor | Hwang, Yu Kyeong | - |
dc.contributor.nonIdAuthor | Kim, Won Seog | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | MG4101 | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordAuthor | B cell non-Hodgkin lymphoma | - |
dc.subject.keywordPlus | NK CELLS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | INTERLEUKIN-2 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.